Whitehead Kathryn, Shen Zancong, Mitragotri Samir
Department of Chemical Engineering, University of California, Engineering II building, Santa Barbara 93106, USA.
J Control Release. 2004 Jul 23;98(1):37-45. doi: 10.1016/j.jconrel.2004.04.013.
Oral drug delivery, though attractive compared to injections, cannot be utilized for the administration of peptides and proteins due to poor epithelial permeability and proteolytic degradation within the gastrointestinal tract. A novel method is described that utilizes mucoadhesive intestinal patches to deliver therapeutic doses of insulin into systemic circulation. Intestinal patches localize insulin near the mucosa and protect it from proteolytic degradation. In vitro experiments confirmed the secure adhesion of patches to the intestine and the release of insulin from the patches. In vivo experiments performed via jejunal administration showed that intestinal insulin patches with doses in the range of 1-10 U/kg induced dose-dependent hypoglycemia in normal rats with a maximum drop in blood glucose levels of 75% observed at a dose of 10 U/kg. These studies demonstrate that reduction in blood glucose levels comparable to that induced by subcutaneous injections can be achieved via enteral insulin absorption with doses only 2-10-fold higher than subcutaneous doses.
口服给药虽然与注射给药相比具有吸引力,但由于胃肠道上皮渗透性差和蛋白水解降解,不能用于肽和蛋白质的给药。本文描述了一种利用粘膜粘附性肠贴片将治疗剂量的胰岛素输送到体循环的新方法。肠贴片将胰岛素定位在粘膜附近,并保护其免受蛋白水解降解。体外实验证实了贴片与肠道的牢固粘附以及胰岛素从贴片中释放。通过空肠给药进行的体内实验表明,剂量在1-10 U/kg范围内的肠胰岛素贴片在正常大鼠中诱导剂量依赖性低血糖,在10 U/kg的剂量下观察到血糖水平最大下降75%。这些研究表明,通过肠内胰岛素吸收,仅需比皮下剂量高2-10倍的剂量,就可以实现与皮下注射相当的血糖水平降低。